Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.58
-5.53 (-2.63%)
AAPL  266.77
+2.19 (0.83%)
AMD  195.00
-5.15 (-2.57%)
BAC  51.37
-1.69 (-3.19%)
GOOG  310.77
-4.13 (-1.31%)
META  638.86
-16.80 (-2.56%)
MSFT  384.25
-12.98 (-3.27%)
NVDA  190.46
+0.64 (0.34%)
ORCL  139.70
-8.38 (-5.66%)
TSLA  394.74
-17.08 (-4.15%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.